OsteoarthritisNCT07360457
GLP1 Analogues and the Risk of Osteoarthritis
An observational study of Osteoarthritis, run by Beni-Suef University.
Trial summary
Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Osteoarthritis
- What is being tested?
- GLP-1 analog, SGLT2 inhibitor and Antidiabetic
- How many people
- 390 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2026to 1 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 130 T2DM patients will be admitted in each group Group 1 : T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care Group 2: T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care Group 3: T2DM patients receiving only standard of care
Who may be able to join
- Adults aged above 50 years old with a previous diagnosis of T2DM according to ADA 2025, who have been on either SGLT2 inhibitors or GLP-1 analogs for at least one year.
Who cannot join
- individuals with Type 1 Diabetes Mellitus
- non-diabetic individuals
- those taking prandial insulin
- patients with arthritis without osteoarthritis,
- those taking other medications contraindicated with study medications,
- pregnant or breastfeeding females
- those allergic to active ingredients,
- those using corticosteroids, Autoimmune disease patients or patients receiving immunotherapies, monoclonal antibody targeting TNF-α or IL-6.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients
Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.
Read the detailed description
Osteoarthritis (OA) is a multifactorial joint disease related to multiple inflammatory pathways which are triggered by mechanical and cellular stress, leading to increased production of pro-inflammatory mediators, reactive oxygen species, advanced glycation end products (AGEs). These mediators promote the release of proteolytic enzymes, which degrade the cartilage matrix. A recent study emphasized on the relation between metabolic syndrome and OA, considering metabolic dysregulation as a major factor in OA progression.
GLP-1 receptor agonists lower blood sugar by boosting glucose-dependent insulin release, reducing glucagon secretion, and slowing stomach emptying. GLP-1RA is present in both healthy and osteoarthritic cartilage, indicating a direct effect on chondrocytes. so it can decrease the accumulation of AGEs, which is the main cause of OA. It also reduces appetite, leading to weight loss which decreases the mechanical stress on joints. GLP downregulates proinflammatory cytokines (IL-6, TNF-a). also inhibits NF-κB pathway. which has a role in promoting osteoclast formation, so GLP plays a protective role in OA.
- Conditions
- Osteoarthritis
- Being tested
- GLP-1 analog, SGLT2 inhibitor, Antidiabetic
- Keywords
- GLP-1
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 analogDrug
Also called GLP1 receptor agonist
glucagon like peptide analogues
SGLT2 inhibitorDrug
Also called gliflozin
sodium glucose transporter-2 inhibitors
AntidiabeticDrug
Also called Control
Standard of care
| Study group | Role | What they receive |
|---|---|---|
| SGLT2 Group | T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care Receives: Drug: SGLT2 inhibitor | |
| GLP1 Group | T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care Receives: Drug: GLP-1 analog | |
| Control group | T2DM patients receiving only standard of care Receives: Drug: Antidiabetic |
What is being measured
The primary outcome is the main question the study is designed to answer.
WOMAC score
A validated, self-administered questionnaire used to assess pain, stiffness, and physical function
Measured: at Day 1
Secondary outcomes (1)
VAS pain score
numerical measure to assess pain
Measured: at Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start1 Feb 2026 (estimated)
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 390 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Asmaa Abdelfattah Elsayed, Beni-Suef University
- Investigators
- Asmaa Elsayed, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07360457
- Sponsor's protocol ID
- GLP1
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2026
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients
- ClinicalTrials.gov ID
- NCT07360457
- Acronym / sponsor ID
- GLP1
- Conditions
- Osteoarthritis
- Keywords
- GLP-1
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 390 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.
Detailed description
Osteoarthritis (OA) is a multifactorial joint disease related to multiple inflammatory pathways which are triggered by mechanical and cellular stress, leading to increased production of pro-inflammatory mediators, reactive oxygen species, advanced glycation end products (AGEs). These mediators promote the release of proteolytic enzymes, which degrade the cartilage matrix. A recent study emphasized on the relation between metabolic syndrome and OA, considering metabolic dysregulation as a major factor in OA progression.
GLP-1 receptor agonists lower blood sugar by boosting glucose-dependent insulin release, reducing glucagon secretion, and slowing stomach emptying. GLP-1RA is present in both healthy and osteoarthritic cartilage, indicating a direct effect on chondrocytes. so it can decrease the accumulation of AGEs, which is the main cause of OA. It also reduces appetite, leading to weight loss which decreases the mechanical stress on joints. GLP downregulates proinflammatory cytokines (IL-6, TNF-a). also inhibits NF-κB pathway. which has a role in promoting osteoclast formation, so GLP plays a protective role in OA.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| SGLT2 Group | – | Drug: SGLT2 inhibitorT2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care |
| GLP1 Group | – | Drug: GLP-1 analogT2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care |
| Control group | – | Drug: AntidiabeticT2DM patients receiving only standard of care |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 130 T2DM patients will be admitted in each group Group 1 : T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care Group 2: T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care Group 3: T2DM patients receiving only standard of care
Key inclusion criteria (1 listed)
- Adults aged above 50 years old with a previous diagnosis of T2DM according to ADA 2025, who have been on either SGLT2 inhibitors or GLP-1 analogs for at least one year.
Key exclusion criteria (8 listed)
- individuals with Type 1 Diabetes Mellitus
- non-diabetic individuals
- those taking prandial insulin
- patients with arthritis without osteoarthritis,
- those taking other medications contraindicated with study medications,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1 analogAlso: GLP1 receptor agonistglucagon like peptide analogues | Drug | GLP1 Group |
| SGLT2 inhibitorAlso: gliflozinsodium glucose transporter-2 inhibitors | Drug | SGLT2 Group |
| AntidiabeticAlso: ControlStandard of care | Drug | Control group |
Primary outcome
WOMAC score
Time frame: at Day 1
A validated, self-administered questionnaire used to assess pain, stiffness, and physical function
1 secondary outcome
VAS pain score
Time frame: at Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Asmaa Elsayed principal investigator
Sohag University
Questions about this trial
What is this clinical trial studying?
An observational study of Osteoarthritis, run by Beni-Suef University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Asmaa A Elsayed (01095727201, asmaa.abdelfattah@pharm.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
WOMAC score (time frame: at Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.